However, at the current stage, the development of drugs based on GPR120 agonists for the treatment of patients with obesity-related disorders requires conducting many large-scale clinical trials and solving the above-mentioned problems. Here, FFAR4 is linked to obesity due to melanocortin 4 receptor deficiency.